Status:
COMPLETED
Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Lead Sponsor:
Alexandria University
Conditions:
Rectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The National Comprehensive Cancer Network (NCCN) guidelines recommend trimodality treatment for patients with middle and low LARC with neoadjuvant chemoradiotherapy (NA-CRT), surgical resection with T...
Detailed Description
Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in men and women in the USA. Surgery using the total mesorectal excision (TME) remains the co...
Eligibility Criteria
Inclusion
- Clinical diagnosis of rectal cancer
- Inferior margin within 12 cm from the anal verge
- staging must be T3-4,N0 or any T, N +ve
Exclusion
- Recurrent or metastatic disease.
- Rectal cancer on top of IBD.
- Hereditary non-polyposis colorectal cancer (HNPCC), or hereditary rectal cancer
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT05274945
Start Date
January 1 2020
End Date
January 1 2022
Last Update
March 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed Samir Ashoor
Alexandria, Egypt